# US 2017/0319695 A1 · Compositions and methods for treating cns disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0319695 A1
- Document ID: US20170319695A1
- Status: Published application
- Kind: A1
- Application number: 15/660,114
- Filed: 2017-07-26
- Published: 2017-11-09
- Earliest claimed: 2015-01-26
- Assignees: Sage Therapeutics, Inc.
- Applicants: Sage Therapeutics, Inc.
- Inventors: Albert J. Robichaud; Gabriel Martinez Botella; Francesco G. Salituro; Boyd L. Harrison
- Web page: https://patentgrep.com/patent/US20170319695A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 23/00: Anaesthetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 27/16: Otologicals
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07J 3/00: Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J 3/005: {the carbon atom being part of a carboxylic function}
- C07J 7/002: {not substituted in position 16}
- C07J 7/007: {not substituted in position 17 alfa}
- C07J 7/0085: {by an halogen atom}
- C07J 7/009: {by only one oxygen atom doubly bound}
- C07J 13/007: {with double bond in position 17 (20)}
- C07J 41/0044: {with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group}
- C07J 43/003: {not condensed}
- C07J 51/00: Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- C07J 9/00: Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein , A, R1, R2, and R3 are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use, e.g., for treating a subject suffering from a disease or disorder described herein.

## Claims

### Claim 1

A compound of the Formula (I):
or a pharmaceutically acceptable salt thereof;
wherein:
Ring A is aryl or heteroaryl;
R1 is hydrogen, C1-3 alkyl, C2-6 alkenyl, or C3-6 carbocylyl;
R2 is absent or hydrogen;
R3 is hydrogen, alkyl, or —CH2OR3A, wherein RA3 is hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, or C3-6 carbocyclyl;
represents a single or double bond, wherein when one is a double bond, the other is a single bond;
wherein when R1 is —CH3, R2 is hydrogen in the alpha configuration, and R3 is —CH3, then A is aryl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound of Formula (I) is a compound of Formula (I-a):
wherein:
n is 0, 1, 2, 3, 4, or 5;
Ra is halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, —C(O)RA, —C(O)ORA, —C(O)NRBRC, —S(O)2RD, or —ORY, wherein RY is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, —C(O)RA, —C(O)ORA, —C(O)NRBRC, or —S(O)2RD;
RA is hydrogen, C1-C6 alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl;
each of RB and RC is independently hydrogen, C1-C6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, or taken together with the atom to which they are attached form a ring; and
RD is hydrogen, C1-C6 alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl.

### Claim at position 3

3-20. (canceled)

### Claim 21 (depends on 2)

The compound of claim 2, wherein the compound of Formula (I-a) is selected from:

### Claim 22 (depends on 1)

The compound of claim 1, wherein the compound of Formula (I) is a compound of Formula (I-b):
wherein:
n is 0, 1, 2, 3, 4, or 5;
Ra is halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, —C(O)RA, —C(O)ORA, —C(O)NRBRC, —S(O)2RD, or —ORY, wherein RY is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, —C(O)RA, —C(O)ORA, —C(O)NRBRC, or —S(O)2RD;
RA is hydrogen, C1-C6 alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl;
each of RB and RC is independently hydrogen, C1-C6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, or taken together with the atom to which they are attached form a ring; and
RD is hydrogen, C1-C6 alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl.

### Claim 23 (depends on 22)

The compound of claim 22, wherein the compound of Formula (I-b) is a compound of Formula (I-b-i), (I-b-ii), (I-b-iii), or (I-b-iv):

### Claim at position 7

24-41. (canceled)

### Claim 42 (depends on 22)

The compound of claim 22, wherein the compound of Formula (I-b) is selected from:

### Claim 43 (depends on 42)

The compound of claim 42, wherein the compound of Formula (I) is a compound of Formula (I-c):
wherein:
n is 0, 1, 2, 3, 4, or 5;
Ra is halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, —C(O)RA, —C(O)ORA, —C(O)NRBRC, —S(O)2RD, or —ORY, wherein RY is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, —C(O)RA, —C(O)ORA, —C(O)NRBRC, or —S(O)2RD;
RA is hydrogen, C1-C6 alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl;
each of RB and RC is independently hydrogen, C1-C6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, or taken together with the atom to which they are attached form a ring; and
RD is hydrogen, C1-C6 alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl.

### Claim 44 (depends on 43)

The compound of claim 43, wherein the compound of Formula (I-c) is a compound of Formula (I-c-i), (I-c-ii), (I-c-iii), or (I-c-iv):

### Claim at position 11

45-62. (canceled)

### Claim 63 (depends on 44)

The compound of claim 44, wherein the compound of Formula (I-c) is selected from:

### Claim 64 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

### Claim 65

A method of inducing sedation and/or anesthesia in a subject, comprising administering to the subject an effective amount of a compound of the Formula (I):
or a pharmaceutically acceptable salt thereof;
wherein:
Ring A is aryl or heteroaryl;
R1 is hydrogen, C1-3 alkyl, C2-6 alkenyl, or C3-6 carbocylyl;
R2 is absent or hydrogen;
R3 is hydrogen, alkyl, or —CH2OR3A, wherein R3A is hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl heteroaryl, or C3-6 carbocyclyl;
represents a single or double bond, wherein when one is a double bond, the other is a single bond;
wherein when R1 is —CH3, R2 is hydrogen in the alpha configuration, and R3 is —CH3, then A is aryl.

### Claim 66 (depends on 1)

A method of administering an effective amount of a compound, a pharmaceutically acceptable salt thereof, or pharmaceutical composition of a compound of claim 1, to a subject in need thereof, wherein the subject experiences sedation and/or anesthesia within two hours of administration.

### Claim 67 (depends on 66)

The method of claim 66, wherein the subject experiences sedation and/or anesthesia within one hour of administration.

### Claim 68 (depends on 66)

The method of claim 66, wherein the subject experiences sedation and/or anesthesia instantaneously.

### Claim 69 (depends on 66)

The method of claim 66, wherein the compound is administered by intravenous administration.

### Claim 70 (depends on 66)

The method of claim 66, wherein the compound is administered chronically.

### Claim 71 (depends on 66)

The method of claim 66, wherein the subject is a mammal.

### Claim 72 (depends on 71)

The method of claim 71, wherein the subject is a human.

### Claim 73 (depends on 66)

The method of claim 66, wherein the compound is administered in combination with another therapeutic agent.

### Claim 74

A method for treating seizure in a subject, comprising administering to the subject an effective amount of a compound of the Formula (I):
or a pharmaceutically acceptable salt thereof;
wherein:
Ring A is aryl or heteroaryl;
R1 is hydrogen, C1-3 alkyl, C2-6 alkenyl, or C3-6 carbocylyl;
R2 is absent or hydrogen;
R3 is hydrogen, alkyl, or —CH2OR3A, wherein R3A is hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, or C3-6 carbocyclyl;
represents a single or double bond, wherein when one is a double bond, the other is a single bond;
wherein when R1 is —CH3, R2 is hydrogen in the alpha configuration, and R3 is —CH3, then A is aryl.

### Claim 75

A method for treating epilepsy in a subject, the method comprising administering to the subject an effective amount of a compound of the Formula (I):
or a pharmaceutically acceptable salt thereof;
wherein:
Ring A is aryl or heteroaryl;
R1 is hydrogen, C1-3 alkyl, C2-6 alkenyl, or C3-6 carbocylyl;
R2 is absent or hydrogen;
R3 is hydrogen, alkyl, or —CH2OR3A, wherein R3A is hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, or C3-6 carbocyclyl;
represents a single or double bond, wherein when one is a double bond, the other is a single bond;
wherein when R1 is —CH3, R2 is hydrogen in the alpha configuration, and R3 is —CH3, then A is aryl.

### Claim 76

A method for treating status epilepticus (SE) in a subject, the method comprising administering to the subject an effective amount of a compound of the Formula (I):
or a pharmaceutically acceptable salt thereof;
wherein:
Ring A is aryl or heteroaryl;
R1 is hydrogen, C1-3 alkyl, C2-6 alkenyl, or C3-6 carbocylyl;
R2 is absent or hydrogen;
R3 is hydrogen, alkyl, or —CH2OR3A, wherein R3A is hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, or C3-6 carbocyclyl;
represents a single or double bond, wherein when one is a double bond, the other is a single bond;
wherein when R1 is —CH3, R2 is hydrogen in the alpha configuration, and R3 is —CH3, then A is aryl.

### Claim 77 (depends on 76)

The method of claim 76, wherein the status epilepticus is convulsive status epilepticus or non-convulsive status epilepticus.

### Claim 78

(canceled)

### Claim 79

A method for treating a CNS-related disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I):
or a pharmaceutically acceptable salt thereof;
wherein:
Ring A is aryl or heteroaryl;
R1 is hydrogen, C1-3 alkyl, C2-6 alkenyl, or C3-6 carbocylyl;
R2 is absent or hydrogen;
R3 is hydrogen, alkyl, or —CH2OR3A, wherein R3A is hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, or C3-6 carbocyclyl;
represents a single or double bond, wherein when one is a double bond, the other is a single bond;
wherein when R1 is —CH3, R2 is hydrogen in the alpha configuration, and R3 is —CH3, then A is aryl.

### Claim 80 (depends on 79)

The method of claim 79, wherein the CNS-related disorder is a sleep disorder, a mood disorder, a schizophrenia spectrum disorder, a convulsive disorder, a disorder of memory and/or cognition, a movement disorder, an anxiety disorder, a personality disorder, autism spectrum disorder, pain, traumatic brain injury, a vascular disease, a substance abuse disorder and/or withdrawal syndrome, or tinnitus.

### Claim 81 (depends on 79)

The method of claim 79, wherein the compound is administered orally.

### Claim 82 (depends on 79)

The method of claim 79, wherein the compound is administered intramuscularly.

### Claim 83 (depends on 79)

The method of claim 79, wherein the subject is a subject with Rett syndrome, Fragile X syndrome, or Angelman syndrome.

### Claim at position 33

84-100. (canceled)

### Claim 101

A kit comprising a solid composition comprising a compound of Formula (I):
or a pharmaceutically acceptable salt thereof;
wherein:
Ring A is aryl or heteroaryl;
R1 is hydrogen, C1-3 alkyl, C2-6 alkenyl, or C3-6 carbocylyl;
R2 is absent or hydrogen;
R3 is hydrogen, alkyl, or —CH2OR3A, wherein R3A is hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, or C3-6 carbocyclyl;
represents a single or double bond, wherein when one is a double bond, the other is a single bond;
wherein when R1 is —CH3, R2 is hydrogen in the alpha configuration, and R3 is —CH3, then A is aryl.
